Core Viewpoint - The report outlines the findings from the on-site inspection conducted by Huatai United Securities on Prasis (Shanghai) Pharmaceutical Technology Development Co., Ltd. for the first half of 2025, confirming compliance with various regulatory requirements and internal controls [1][2][3] Group 1: Company Governance - The inspection confirmed that the company governance documents, including business registration files and articles of association, were complete and properly maintained [1] - The company’s board meetings and related resolutions were reviewed, ensuring compliance with execution and disclosure obligations [1][2] Group 2: Internal Control - The internal audit department's structure and operational effectiveness were assessed, with no significant issues found [1][2] - The audit committee's documentation and the execution of the internal audit work plan were also reviewed, confirming adherence to established procedures [1][2] Group 3: Information Disclosure - The company’s information disclosure archives and related supporting documents were examined, ensuring compliance with disclosure management regulations [2] Group 4: Protection of Company Interests - The establishment and execution of mechanisms to protect the company’s interests, particularly regarding related party transactions and external guarantees, were verified [2] Group 5: Use of Raised Funds - The inspection included a review of the bank statements for the special account for raised funds, confirming proper usage in line with disclosed purposes [2] Group 6: Performance Situation - Discussions with management provided insights into the company's operational status and significant changes, with financial statements and major contracts reviewed for accuracy [2] Group 7: Commitment Fulfillment - The commitments made by the company and its shareholders were checked for compliance, with no issues reported [2][3] Group 8: Other Important Matters - Additional inquiries into the company's operational conditions and large fund payment approval processes were conducted, with no significant findings [3]

Meeting Overview - The shareholder meeting of Anhui Wanbang Pharmaceutical Technology Co., Ltd. was held on August 21, 2025, with a total share capital of 66,261,767 shares, and 62.8712% of shares represented at the meeting [1][2] Voting Participation - A total of 4 shareholders participated in the on-site voting, representing 41,493,950 shares, which is 62.7493% of the voting shares [2] - 59 small shareholders participated through online voting, representing 165,600 shares, which is 0.2499% of the voting shares [2] Resolutions Passed - The proposal to amend the company's articles of association was approved with 99.7312% of the votes in favor, totaling 41,547,550 shares [3][4] - The proposal to revise and establish certain governance systems was also approved with 99.7369% of the votes in favor, totaling 41,549,950 shares [5][6] - The proposal to renew the audit firm for the year 2025 was approved with 99.7360% of the votes in favor, totaling 41,549,550 shares [7] Board Elections - The election of the third board of directors was conducted using cumulative voting, with 41,501,458 votes in favor, representing 99.6205% of the valid votes [8][9] - The election results for non-independent directors included Ms. Tao Chunlei and Mr. Xu Xinluo, both receiving over half of the votes [8][9] - The election results for independent directors included Mr. Zhang Hongbin and Ms. Zhuo Min, both also receiving over half of the votes [9][10] Legal Opinion - The legal opinion provided by Anhui Chengyi Law Firm confirmed that the meeting's procedures, attendance, and voting processes complied with legal and regulatory requirements [10]

Core Viewpoint - The legal opinion letter confirms the legality of the procedures and results of Anhui Wanbang Pharmaceutical Technology Co., Ltd.'s second extraordinary general meeting of shareholders in 2025, ensuring compliance with relevant laws and regulations [2][4][6]. Group 1: Meeting Procedures - The second board meeting of the company on August 4, 2025, resolved to convene the extraordinary general meeting and published the notice detailing the time, location, and agenda [2]. - The meeting was conducted through a combination of on-site and online voting, with specific time slots for network voting provided [3]. - The meeting was chaired by the company's chairman, Ms. Tao Chunlei, and all procedural aspects were found to be consistent with the published notice [3][4]. Group 2: Attendance and Qualifications - A total of 63 shareholders attended the meeting, representing 41,659,550 shares, which accounted for 62.8712% of the total voting shares [4]. - The qualifications of the attendees and the convenor were verified and deemed compliant with the Company Law and relevant regulations [4][5]. Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online methods, with results being counted and announced immediately [5]. - The proposal to amend the company's articles of association received 41,547,550 votes in favor, representing 99.7312% of the valid votes [5][6]. - Other proposals, including the appointment of the auditing firm and the election of the board of directors, also passed with similar overwhelming support [6][7]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendance, and voting procedures, were in accordance with legal requirements, rendering the results valid [8].

Group 1 - The company will hold a half-year performance briefing on August 28, 2025, from 09:00 to 10:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Investors can submit questions from August 22 to August 27, 2025, and the company will address common concerns during the briefing [1][2] Group 2 - Key participants in the briefing include the Chairman and General Manager, Mr. Cai Xiangting, and other board members [2] - Investors can access the briefing online through the Shanghai Stock Exchange Roadshow Center [2][3] - After the briefing, investors can review the main content and outcomes on the Shanghai Stock Exchange Roadshow Center website [3]

Group 1 - The core theme of the event is "Medical Health Full-Scenario Intelligent Systems," showcasing five major industry intelligent systems by Zhongkang Technology [1] - The drugstore intelligent system and commercial intelligent system attracted significant attention with immersive experience zones, highlighting Zhongkang's leading position in the AI healthcare sector [1] Group 2 - Zhongkang Technology officially released a major upgrade plan for the Zhongkang Drugstore Intelligent System, focusing on five core intelligent systems for collaborative evolution [2] - The upgrade aims to transform the drugstore model from a simple medication provider to a "smart health steward," marking the entry of the pharmaceutical retail industry into an "algorithm-driven" era [2] - The full-chain AI decision-making system is constructed based on vast industry data, enhancing operational insights, member management, product improvement, staff empowerment, and disease management [2] Group 3 - Zhongkang Technology introduced a product matrix of commercial AI intelligent systems, including super individual intelligent systems, AI digital marketing growth platforms, and industrial marketing digital foundations [3] - The solutions empower pharmaceutical companies across marketing decision-making, sales execution, and terminal operations, achieving a sevenfold efficiency increase [3] - The complete value closed loop covers data governance, intelligent applications, and business implementation, redefining digital transformation standards in the pharmaceutical industry [3]

Group 1 - The core point of the news is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 66,200 shares at an average price of HKD 53.8841 per share, resulting in a total investment of approximately HKD 3.5671 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 14.8183 million shares, increasing its ownership percentage from 11.98% to 12.04% [1]

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 1.1816 million shares at an average price of HKD 55.9087 per share, totaling approximately HKD 66.0617 million [1] - After the purchase, E Fund's total shareholding in Tiger Med increased to 13.8033 million shares, raising its ownership percentage from 10.25% to 11.21% [1][2]

Group 1 - Shanghai Mixine Pharmaceutical Technology Development Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company is wholly owned by *ST Sailong, indicating a potential strategic alignment or investment focus [1] - The business scope includes a variety of services such as technology development, medical research, food sales, and the production and sales of medical devices [1] Group 2 - The company is authorized to engage in the production and wholesale of pharmaceuticals, as well as the import and export of drugs [1] - The operational activities are subject to approval from relevant authorities, ensuring compliance with regulatory standards [1] - The company’s activities also encompass market research, marketing planning, and various consulting services [1]

Group 1 - The company, Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., has recently obtained CE certification for five of its products, allowing them to be sold in the EU and European Economic Area (EEA) markets [1] - The certification will facilitate entry into other international markets that recognize or reference EU standards, thereby broadening the overseas application scenarios for the company's products [1] - The company has also secured market access qualifications in multiple countries and regions, including Japan, Ukraine, Ecuador, and Vietnam, and plans to accelerate its international expansion [1]

| 1255 | 铸造有法见的磷业传 泰格仁达(上海)医药科技有限公司 | | 0 道一下 | ■ 应用 · | 企业中心 | E 10 | × 5VIP 骨贤服务 | | --- | --- | --- | --- | --- | --- | --- | --- | | 基本信息 6 | 法律诉讼 | 经营风险 | 经营信息 企业发展 | | 知识产权 | | MP 历史信息 ( | | 统一社会倡用代码 | 91310105MAERKQJP28 | 企业各称 | 颜格仁达(上海)医药科技有限公司 | | | | | | | | 登记状态 | 存法 | 成立日期 | 2025-07-28 | | | | 法定代表人 | 费观看 关联企业 57 | 注册资本 | 200万元 | 女被避手 | = | | | | 组织机构代码 | MAERKQJP-2 | 工岗注册号 | 310105000905104 | 纳税人旧别号 | | 91310105MAERKQJP28 | | | 企业类型 | 有限责任公司(非目然人投资成控股 的法人般资) | 實业明顯 | 2025-07-28 至 2045-07-27 | 的 ...